Mirum Pharmaceuticals (MIRM) announced that its partner, Takeda (TAK), has received approval by the Japanese Ministry of Health, Labour, and Welfare for Livmarli oral solution for the treatment of cholestatic pruritus in patients with Alagille syndrome and Progressive Familial Intrahepatic Cholestasis in Japan.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MIRM:
- Mirum Pharmaceuticals: Promising Growth Trajectory with Strategic Focus and Pipeline Progress
- Mirum Pharmaceuticals: Strong Buy Rating Driven by Promising Financial Growth and Clinical Advancements
- Mirum Pharmaceuticals’ Earnings Call Highlights Growth and Future Prospects
- Mirum Pharmaceuticals price target raised to $65 from $63 at Morgan Stanley
- Mirum Pharmaceuticals price target raised to $55 from $50 at Baird